{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:14:39Z","timestamp":1763705679129,"version":"3.44.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1053\/j.seminoncol.2019.11.002","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:34:13Z","timestamp":1574123653000},"page":"408-413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cardio-oncological management of patients"],"prefix":"10.1053","volume":"46","author":[{"given":"Daniela M.","family":"Cardinale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Barac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Torbicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bijoy K.","family":"Khandheria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Lenihan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Minotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2019.11.002_bib0001","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11912-017-0610-9","article-title":"Cardio-oncology: gaps in knowledge, goals, advances, and educational efforts","volume":"19","author":"Biasillo","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0002","first-page":"309","article-title":"Cardiotoxicity of anticancer treatments: epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0003","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11886-016-0731-z","article-title":"Curing cancer, saving the heart: a challenge that cardioncology should not miss","volume":"18","author":"Cardinale","year":"2016","journal-title":"Curr Cardiol Rep"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0004","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0005","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S1470-2045(17)30535-1","article-title":"Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?","volume":"18","author":"Levis","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0006","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s11886-013-0362-6","article-title":"Cardiac toxicity of anticancer agents","volume":"15","author":"Colombo","year":"2013","journal-title":"Curr Cardiol Rep"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0007","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0008","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/14737159.2017.1283219","article-title":"Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy","volume":"17","author":"Cardinale","year":"2017","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0009","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0010","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","article-title":"Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial","volume":"94","author":"Cardinale","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0011","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2018.04.003","article-title":"The International Cardioncology Society-ONE trial: not all that glitters is for cardioncologists only","volume":"97","author":"Minotti","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0012","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJM197902083000603","article-title":"Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography","volume":"300","author":"Alexander","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0013","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/0002-9343(87)90212-9","article-title":"Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography","volume":"82","author":"Schwartz","year":"1987","journal-title":"Am J Med"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0014","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0015","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0016","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jchf.2017.08.024","article-title":"Left ventricular dysfunction in cancer treatment: is it relevant?","volume":"6","author":"Kenigsberg","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0017","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0018","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0019","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0020","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1200\/JCO.2015.64.5515","article-title":"Cardiac surveillance guidelines for trastuzumab-containing therapy in early-stage breast cancer: getting to the heart of the matter","volume":"34","author":"Dang","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0021","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2\u00d72 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0022","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0023","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy related cardiotoxicity","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0024","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004560","article-title":"Left ventricular mass change after anthracycline chemotherapy","volume":"11","author":"Jordan","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0025","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1161\/CIRCULATIONAHA.116.023463","article-title":"Detailed echocardiographic phenotyping in breast cancer patients: associations with ejection fraction decline, recovery, and heart failure symptoms over 3 years of follow-up","volume":"135","author":"Narayan","year":"2017","journal-title":"Circulation"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0026","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.amjcard.2012.07.040","article-title":"Left ventricular mass in patients with cardiomyopathy after treatment with anthracyclines","volume":"110","author":"Neilan","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0027","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jcmg.2018.03.019","article-title":"Rationale and design of the strain surveillance of chemotherapy for improving cardiovascular outcomes: the SUCCOUR Trial","volume":"11","author":"Negishi","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0028","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0029","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J Am Col Cardiol"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0030","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jacc.2010.07.023","article-title":"Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies: are clinicians responding optimally?","volume":"56","author":"Yoon","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0031","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ijcard.2017.02.154","article-title":"Practices in management of cancer treatment-related cardiovascular toxicity: a cardio-oncology survey","volume":"241","author":"Jovenaux","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0032","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.104.470849","article-title":"Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth","volume":"111","author":"Kirchmair","year":"2005","journal-title":"Circulation"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0033","first-page":"72","article-title":"The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients","volume":"1","author":"Hall","year":"2013","journal-title":"J Am Coll Cardiol-Heart Fail"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0034","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2015.10.008","article-title":"Statins and survival outcomes in patients with metastatic renal cell carcinoma","volume":"52","author":"McKay","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0035","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminoncol.2019.10.005","article-title":"Mechanisms and clinical course of cardiovascular toxicity of cancer treatment. II. Hematology","author":"Breccia","year":"2019","journal-title":"Sem Oncol"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0036","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1106180","article-title":"Proteotoxicity and cardiac dysfunction","volume":"368","author":"Willis","year":"2013","journal-title":"New Eng J Med"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0037","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.drudis.2010.01.008","article-title":"Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy","volume":"15","author":"Dick","year":"2010","journal-title":"Drug Discov Today"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0038","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cardfail.2014.11.008","article-title":"Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma","volume":"21","author":"Grandin","year":"2015","journal-title":"J Card Fail"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0039","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0040","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0041","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1161\/CIRCULATIONAHA.115.018351","article-title":"Cardiovascular complications of novel multiple myeloma treatments","volume":"133","author":"Li","year":"2016","journal-title":"Circulation"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0042","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2019.11.002_bib0043","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminoncol.2019.10.006","article-title":"Mechanisms and clinical course of cardiovascular toxicity of cancer treatment. I","author":"Yeh","year":"2019","journal-title":"Oncology. Sem Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775419300090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775419300090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:54:34Z","timestamp":1758804874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775419300090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0093775419300090"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2019.11.002","relation":{},"ISSN":["0093-7754"],"issn-type":[{"type":"print","value":"0093-7754"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardio-oncological management of patients","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2019.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}